



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

APR 12 2001

RECEIVED

In re Application of:

Gudmundur Johannsson et al.

Serial No.: 09/050,366

Art Unit: 1653

Filed: March 31, 1998

Examiner: Moezie, F.

For: USE OF GROWTH HORMONE

Atty Docket: 0151/00211

RESPONSE AND AMENDMENT UNDER 37 CFR § 1.111

Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action dated March 14, 2001, please amend the above-identified application as follows:

Please amend the claims as follows.

22. (Thrice amended) A method of treating a patient for insulin resistance, said patient having the Metabolic Syndrome, wherein said syndrome comprises Primary Insulin Resistance and abdominal/visceral obesity, wherein said method comprises administering to said patient growth hormone or a functional derivative thereof in an amount effective for decreasing insulin resistance of said patient.

REMARKS

Claims 22-24, 28, and 41 are now pending in the application.

Claim 22 has been amended to conform wording of the preamble to the wording of the preamble of the earlier elected Group. The amendment specifically does not address, modify, or alter any claim element.